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Abstract  
Objective 
Genome-wide association studies (GWAS) have identified over 30 susceptibility loci 
associated with Alzheimer’s disease (AD).  Using AD GWAS data from the International 
Genomics of Alzheimer’s Project (IGAP), Polygenic Risk Score (PRS) was successfully 
applied to predict life time risk of AD development. A recently introduced Polygenic 
Hazard Score (PHS) is able to quantify individuals with age-specific genetic risk for AD. 
The aim of this study is to quantify the age-specific genetic risk for AD with PRS and 
compare the results generated by PRS with those from PHS.  
 
Methods 
Quantification of individual differences in age-specific genetic risk for AD identified by 
the PRS, was performed with Cox Regression on 9,903 (2,626 cases and 7,277 controls) 
individuals from the Genetic and Environmental Risk in Alzheimer's Disease consortium 
(GERAD). Polygenic Hazard Scores were generated for the same individuals. The age-
specific genetic risk for AD identified by the PRS was compared with that generated by 
the PHS. This was repeated using varying SNPs p-value thresholds for disease association.  
 
Results 
Polygenic Risk Score significantly predicted the risk associated with age at AD onset 
when SNPs were preselected for association to AD at p≤0.001. The strongest effect 
(B=0.28, SE=0.04, p=2.5x10-12) was observed for PRS based upon genome-wide 
significant SNPs (p≤5x10-8). The strength of association was weaker with less stringent 
SNP selection thresholds.  
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Interpretation 
Both PRS and PHS can be used to predict an age-specific risk for developing AD. The 
PHS approach uses SNP effect sizes derived with the Cox Proportional Hazard Regression 
model. When SNPs were selected based upon AD GWAS case/control p-values ≤10-3, we 
found no advantage of using SNP effects sizes calculated with the Cox Proportional 
Hazard Regression model in our study. When SNPs are selected for association with AD 
risk at p>10-3, the age-specific risk prediction results are not significant for either PRS or 
PHS. However PHS could be more advantageous than PRS of age specific AD risk 
predictions when SNPs are prioritised for association with AD age at onset (i.e. powerful 
Cox Regression GWAS study). 
 
Introduction 
Alzheimer’s disease (AD) is the most common form of neurodegenerative disorder1 with 
over 47 million people affected worldwide and a global economic impact estimated at 
about US $818 billion2. 
 
AD is highly heritable with an estimated 80% of the liability explained by genetic factors3. 
Risk for developing AD involves multiple genetic and environmental components, with 
APOE genotype4 having the strongest genetic effect5. In the last 20 years numerous 
relevant susceptibility loci, genes and pathways have been identified that will improve 
understanding of this complex disease and identify potential therapeutic targets. The 
largest Genome-Wide association study (GWAS) identified more than 20 loci6 associated 
with late (after the age of 65years) onset AD (LOAD). The analysis was extended to 
biological pathways with enrichment in immune response, regulation of endocytosis, 
cholesterol response and proteasome-ubiquitin activity pathways 7.  
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The development and validation of AD prediction algorithms is a very important step 
towards therapeutic strategies for AD prevention and intervention. A polygenic risk score 
(PRS) approach has demonstrated 75%-84% prediction accuracy of AD risk with APOE, 
the polygenic score, sex and age as predictors8,9.  PRS is constructed as a weighted sum 
of allele counts, where the weights are the B-coefficients of SNP association with the 
disease obtained with the Logistic Regression (LR) analysis. Recent development of a 
polygenic hazard score (PHS) approach goes beyond AD risk prediction and provides 
prediction of individual age-specific risk for developing AD10.  Prior to PHS analyses, 
Desikan et al (2017)10 selected SNPs based on their association with AD at p-value≤10-5 
in the publically available IGAP dataset. Then they constructed PHS in a similar way to 
PRS, with the exception that PHS uses log(HR) as SNP risk allele weighs, instead of 
log(OR). Both, log(HR)s and the best PHS model were identified by running step-wise 
Cox regression, yielding 31 SNPs in addition to APOE ε2 and ε4 alleles (see Desikan et 
al (2017)10). 
 
 
LR and Cox Proportional Hazard Regression (Cox regression) analyses are widely used 
in epidemiological studies depending upon the question of interest and available 
information. LR is used to measure the relationship between a binary variable (e.g. 
case/control) and predictor variables, while Cox regression investigates the association 
between the time-to-event (“survival time”) of patients together with other predictor 
variables. Cox regression11 is one of the most-widely applied methods in medical studies 
when investigating time-dependent explanatory variable. Similar to odds ratio (OR) in 
LR, Cox regression estimates the hazard ratio (HR) that is a measure between the 
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probability of events in a ‘case’ group compared to the probability of events in a ‘control’ 
group. The advantage of Cox regression over LR is that the former estimates an 
instantaneous risk for developing AD, based on genotype and age, whilst the latter ignores 
“survival time” and censoring information. 
 
There have been several studies conducted to compare Logistic and Cox regression 
models 12–15. Earlier studies have shown that if the time-to-event data are available, Cox 
proportional hazards models have more statistical power to detect risk factors than LR 
models16, since it accounts for the time until events occur. However, the two models yield 
similar estimates of regression coefficients in studies with short follow‐up (5 years or less) 
time and high survival rate. In addition, although these two regression models have 
different purposes, it has been shown that the risk factors with strong effect size will be 
significant in both models and present similar regression coefficient estimates 14,17.  
The aim of this study is to quantify the age-specific genetic risk for AD with PRS and 
compare the results with PHS. Previously, 31 SNPs in addition to APOE ε2 and ε4 alleles 
were identified10 that were used in deriving PHS and then predicting the age-specific 
individual risk. There are two components in the PHS/PRS analyses, 1) how the individual 
score is generated, i.e. how the SNPs were selected and their effect sizes are derived, and 
2) what aspect of the disease is predicted by this score (age at onset or overall risk).  
 
First we compared the effect sizes of SNP association to AD derived in the same dataset 
using two different models a) Logistic regression and b) Cox regression. To explore the 
second component, we compared the accuracy in quantification of individual differences 
in age-specific genetic risk for AD using PRS, i.e. when the SNP effect sizes are derived 
by LR, and PHS when the effect sizes are derived by Cox regression.  
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Tan et al (2018) in their editorial18 claim that PHS has advantage over PRS to help inform 
disease management decisions for at-risk individuals in the clinic. Our study shows that 
PHS, as constructed in Desikan et al (2017)10 gives very similar results to PRS when tested 
in the Genetic and Environmental Risk for Alzheimer’s disease (GERAD) dataset.  
 
Materials and Methods 
Data 
Generation of PRS (and similar PHS) requires two independent datasets: a discovery 
sample, where the summary statistics are sufficient, and a validation samples, which is 
independent of the discovery sample and contains genotypes for each individual19. We 
compared individual SNP hazard ratio (HR)10 with odds ratios (OR) reported by the 
International genomics of Alzheimer’s project (IGAP) GWAS6. The original IGAP 
summary statistics was derived using a meta-analysis of four GWAS datasets, namely 
European Alzheimer ’s disease Initiative (EADI), Cohorts for Heart and Aging Research 
in Genomic Epidemiology (CHARGE), Alzheimer's Disease Genetics Consortium 
(ADGC) and Genetic and Environmental Risk for Alzheimer’s disease (GERAD) 
consortia.  
 
In this study, since individual genotypes of the GERAD sample were available to us, we 
used GERAD data as the test set. For PRS calculation we used SNP’s log(OR) from the 
meta-analysis of three consortia (EADI, CHARGE and ADGC), excluding GERAD, 
hereby referred to as IGAP_noGERAD. Note that individual SNP effects (B=log(OR)) of 
IGAP_noGEARD dataset were adjusted for age. To generate polygenic hazard scores  in 
the GERAD sample, we used hazards ratio estimates for the 31 SNPs reported in ADGC 
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data10. To test other SNPs, we split the GERAD data and estimated hazards ratios in 75% 
of the data and generated and tested individual scores in the remaining 25% of the data. 
 
The GERAD dataset consists of 3,177 cases and 7,277 controls of Caucasian ancestry (see 
Supplementary Table 1 for cohort statistical characteristics) and partly was published 
previously20. Haplotype Reference Consortium (HRC), version r1.1 2016, was used to 
impute GERAD genotype data on the Michigan Imputation Server21, which to date, allows 
the most accurate imputation of genetic variants. Imputed genotype probabilities (also 
known as dosages) were converted to most probable genotype with a probability threshold 
of 0.9 and greater. SNPs were removed if their imputation INFO-score<0.4, MAF<0.1, 
missingness of genotypes≥0.05 or HWE<10-6. A total of 6,119,694 variants were retained. 
To correct for population structure and genotyping differences, all our analyses were 
adjusted for gender and 3 principle components20.  
 
For the survival analysis model we used age at onset where available, and imputed age at 
onset for the remaining individuals. Imputed age at onset was estimated by subtracting 5 
years from the age of the last assessment (as the mean difference between the age of the 
last assessment and age at onset was 4.7 years in our data). The age at onset has been 
imputed for 253 (8%) cases and for an additional 551 individuals had no age related 
information. Out of the remaining 9,903 individuals (2,626 cases and 7,277 controls), 
APOE genotypes were available for 8,415 individuals (2,384 cases and 6,031 controls) 
and these subjects were included to in the analysis.   
 
To validate the PHS approach in a sample which is independent of ADGC10, we split our 
GERAD data into a discovery (75% or 1934 cases and 5493 controls) dataset, 
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 for estimation the HR, and validation (25% or 692 cases and 1784 controls) dataset, where 
we derived the PHS for each individual and tested for age-specific risk prediction.  
In the GERAD sample 5,570 controls were from the 1958 birth cohort (all included at age 
45) (http://www.b58cgene.sgul.ac.uk), introducing differences in age distribution 
between cases and controls (Figure 1). To avoid a potential bias due to these differences, 
we have repeated the analyses including only participants with age 55 and above, retaining 
4,100 individuals (2,575 cases and 1,525 controls). 
 
Statistical analysis 
We calculated PHS for each subject in our GERAD sample using effect sizes as reported 
in the Desikan et al (2017)10(see fifth column of Table 1). The PRS were generated using 
IGAP_noGERAD effect sizes for the 25 SNPs reported (see seventh column of Table 1). 
To evaluate the contribution of the 25 SNPs over and above APOE ε2 and ε4 risk alleles, 
PHS and PRS were derived in three ways a) only using ε2 and ε4 risk alleles, b) 25 SNPs, 
and c) combining ε2, ε4 and 25 SNPs. We tested whether the addition of either PHS or 
PRS into the Cox regression model improves the model fit over and above APOE ε4 and 
ε2 risk alleles using anova() function in R.  Since APOE is the strongest predictor of AD 
risk, we also validated our results in ε3 homozygous individuals (N=4,368). Furthermore, 
to investigate the stability of the results o for the 25 SNPs of interest, this analysis was 
repeated for randomly selected subsets of cases and controls (20%, 40%, 60%, 80% and 
100% of the whole sample). 
We further investigated whether a different (larger) set of SNPs could improve the power 
of the association and the quality of the prediction of age-specific genetic risk for AD. For 
this we used the full GERAD GWAS dataset (4,997,262 SNPs). The dataset was LD 
pruned with r2=0.1 in a 1000kb window, retaining 167,188 SNPs (with IGAP_noGERAD 
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summary statistics). A five-fold cross-validation approach was employed splitting the 
GERAD data randomly into 75%/25% discovery and validation sets, respectively. LR and 
Cox regression were run in the discovery (75% of GERAD) dataset in order to obtain 
effect sizes, log(OR) and log(HR), respectively. The PRS and PHS for each individual in 
the validation set (25% of GERAD) were generated for AD association p-value thresholds 
of p≤ 5x10-8, 10-5, 10-3, 0.05, 0.1 and 0.5, adjusted for covariates and then standardized. 
The Cox regression model was run to predict age-specific genetic risk for AD by 1) PHS 
and 2) PRS in the validation set. Note, in LR analysis age was not included into the model, 
while Cox regression model has accounted for the age as a censor variable. The 
proportional hazards assumption for the Cox regression model, i.e. that the hazard rate 
ratio is constant over time, was tested using function cox.zph() in R. P-values of the 
proportional hazards assumption tests were non-significant indicating that the models 
were correctly specified. 
 The results of the cross-validation procedure are reported as mean and SD of the effect 
sizes, and as the average of the p-values across cross-validation. We also report the 
average of the correlation coefficients between individual PHS vs PRS scores.  
 
Results 
In attempt to directly replicate the Desikan et al (2017)10 results, we performed analysis 
on 8,415 individuals (2,384 cases and 6,031 controls) for whom APOE genotypes were 
available. PHS was derived for each individual in the GERAD dataset with APOE ε2 and 
ε4 risk alleles and the 25 SNPs available in the dataset that were reported in Desikan et al 
(2017)10 (see also Table 1). PRS was derived using effect sizes obtained from 
IGAP_noGERAD summary statistics using the same SNPs as for PHS. As the effect sizes 
for APOE ε2 and ε4 risk alleles in IGAP_noGERAD data were unavailable, we used 
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GERAD data to estimate them using LR (B(ε2)=-0.66, B(ε4)=1.12). Table 2 presents the 
results of PHS and PRS models, where risk scores were constructed with a) APOE ε4 and 
ε2 risk alleles (columns 2 and 3), b) PHS and PRS scores based upon 25 SNPs (columns 
4 and 5), and c) PHS and PRS scores + APOE ε4 and ε2 risk alleles (columns 6 and 7). It 
can be seen from Table 2 that the regression coefficient estimates (B) and p-values for 
both models are very similar. In both models the strongest association is observed when 
the risk scores (either PHR or PRS) were constructed using APOE ε2 and ε4 risk alleles. 
The scores derived with the 25 SNPs also show significant association with age-specific 
AD risk (p=9.7x10-8, p=1.9x10-10 for PHS and PRS Models, respectively). The last 
column of Table 2 compares the fit of the APOE-alone model with the model using 
APOE+25 SNPs as predictors and shows that the both PHS and PRS significantly improve 
the association results over and above the predictor variable based upon APOE ε2 and ε4 
only. The correlation between individual PHS and PRS was r=0.85 (see Figure 2) and 
even higher when APOE variants were included r=0.99. Analysis in ε3 homozygotes (N 
cases=846, N controls=3522) confirmed that PRS is a significant predictor of age specific 
risk for AD over and above APOE (B=0.17, p=9.5x10-7), and revealed that PHS is a 
slightly less significant predictor (B=0.14, p=2.0x10-5). 
 
Figure 3 shows survival curves for individuals quantified in 5 groups based on 0-5%, 5-
25%, 25-75%, 75-95% and 95-100% of PHS/PRS distributions. Survival curves were 
created using PHS (left panel) and PRS (right panel) accounting for APOE ε2, ε4 risk 
alleles and the 25 SNPs. There is a clear difference in age at onset for individuals that 
belong to different distribution groups for both models. For example, individuals with the 
low PHS (bottom 5% of the PHS distribution, purple line in the left panel of Figure 3) on 
average have 20 years earlier age at onset as compared to the top 5% of the PHS (red line 
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in the left panel of Figure 3), given a probability of 0.25 of developing AD. For both 
models the curves are almost identical and there is clear difference in age at onset for 
individuals that belong to different distribution groups for both models.  
The results of age-specific predictions using PHS and PRS analyses based upon 25 SNPs 
for different sample sizes are presented in Figure 4. As before, the age specific risk effect 
sizes for both PRS and PHS were similar and (as expected) were lowest in the smallest 
subset of the GERAD data, gradually increasing with sample size. 
 
To increase the power of the analysis we attempted to increase the sample size and the 
number of SNPs included in the analysis. We utilised the full GERAD dataset (2,626 cases 
and 7,277 controls), and included APOE locus via the best (imputed) proxies as not all 
individuals in the GEARD sample had direct APOE genotypes. The correlation between 
APOE ε2 allele and rs41290120 was r = 0.74 and between APOE ε4 allele and rs7259620 
was r = -0.41. To include more SNPs into the PHS, we increased the p-value association 
threshold to 0.5 and LD pruned SNPs whilst keeping the most significantly AD-associated 
SNPs (in IGAP_noGERAD) for the analysis. For the pruned SNPs we re-estimated the B 
coefficients with Cox regression and LR in the 75% of the GERAD sample, and ran the 
age specific prediction analyses in the remaining 25% with 5-fold cross-validation (see 
results in Table 3). The Cox regression analysis suggests that significant age-specific 
prediction when using either PHS or PRS is achieved with the SNP selection threshold at 
p≤10-3. The Pearson’s correlation coefficient between individual PHS and PRS is high for 
SNP selection thresholds up to p≤10-5 (Table 3, last column). Age-specific predictions are 
no longer significant when SNPs p-value thresholds are higher than 10-3. Since the age 
distribution was quite different in cases and controls (see Figure 1), the same analyses 
were performed for individuals aged 55 and above, retaining 4,100 samples for the 
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analysis (see results in Table 4). Despite the substantial reduction in sample size, the 
pattern of the results stays the same across tables.  
 
Discussion 
Polygenic risk score approach is typically used to predict risk of the disease and does not 
account for age at onset of cases and the fact that controls may develop the disease later 
in their lives. Implementation of the polygenic hazard score provides prediction for 
individuals’ age-specific risk of AD development and can potentially be used for future 
investigation of the disease progression, intervention and treatment of the disease.  
There are two components to the risk prediction analyses by polygenic scores. The first 
component is the construction of the scores. Both PRS and PHS are derived as a sum of 
the number of risk alleles weighed by the SNP effect sizes, either logarithm of the odds 
ratio (log(OR)) or logarithm of the hazards ratio (log(HR)), respectively, which in turn are 
obtained with two different regression models (Logistic or Cox Proportional Hazard 
regression models). Ideally, for the construction of these scores, the SNP selection should 
be informed by the corresponding summary statistic from an independent dataset. For 
example case/control GWAS results should be used for PRS SNP selection, and Cox 
regression GWAS results, should be used for PHS SNP selection. The second component 
is the actual risk prediction. The choice of the regression model for this component of the 
analysis depends upon the question of interest and available data. If one is interested in 
predicting age-specific risk for AD then PHS should be used as the predictor in the Cox 
regression model, given that the age for controls and age at onset for cases is available for 
the analysis.  
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In this study we tested whether there is an advantage in using PHS over the PRS for age-
specific risk prediction. First, we attempted to directly replicate the results of Desikan et 
al (2017)10 using SNPs available in the GERAD dataset. Then we constructed PRS using 
the same SNPs and tested how well PRS can predict the age-specific risk in the GERAD 
sample. Finally we attempted to enhance the PHS by adding more SNPs related to AD 
risk.  
 
Desikan et al (2017)10 selected AD associated SNPs with p≤10-5 in the IGAP, currently 
the largest publicly available GWAS dataset, then generated individual PHS in their 
(ADGC) dataset and tested this PHS for association with the AD age specific risk. We 
have replicated their findings in our (GERAD) data. These were as expected given 
previous studies, comparing LR and Cox regression14,17, show that the predictors with the 
largest effects stay significant in both Cox and Logistic regression analyses. When the 
effect sizes of the associated SNPs are large, the period between the age at onset and age 
at assessment is short (follow-up period is 5 years or less) and survival rate is high, then 
both Cox regression and LR will show similar estimates of the regression coefficients16. 
A typical AD GWAS design falls into this category. In our data the mean difference 
between the age of the last assessment and age at onset was 4.7 years; there were more 
controls than cases; and the SNPs were selected on the basis of significant association 
with the disease risk. Therefore, it is expected that the IGAP genome-wide significant 
SNPs combined into PHS will show strong association in the ADGC and GERAD datasets 
as these datasets both contribute to the IGAP study.  
 
When the SNPs were selected based upon AD association results in a sample set 
independent of GERAD (IGAP_noGERAD), both PHS and PRS were significantly 
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associated with AD age-specific risk (p-value<10-3). For less stringent significance 
thresholds the age-specific risk prediction was not significant with either PHS or PRS. 
The results of Cox regression analysis have shown no significant difference in model fits 
when using PRS or PHS, if SNPs are selected on the basis of strong association to AD 
risk. However when SNPs are prioritised for association with AD age at onset rather than 
general AD risk by a powerful discovery study (e.g. Cox-regression AD GWAS), the PHS 
is likely to be advantageous over the PRS for age specific AD risk prediction. As such 
discovery study was not available to us, we could not demonstrate this advantage in our 
paper. We emphasise, that this is the main limitation of our study. Since we only had 
access to the AD GWAS summary statistics, obtained with Logistic Regression, we could 
not prioritize SNPs specifically associated with AD age at onset, but only used SNPs 
associated with AD risk overall. To overcome this issue we divided the GERAD data into 
a discovery and validation sub-samples, however this reduced the power of our further 
analyses. Another limitation of this study is the lack of replication in a similar dataset 
since we did not have access to individual genotypes of another AD case/control study 
that was independent from IGAP. To address this limitation, we employed cross-
validation and resampling approaches to the GERAD data. The main results remained 
consistent in all analyses. 
 
In conclusion, when SNPs are selected based upon case/control AD GWAS with p-values 
thresholds up to p≤10-3, comparison of PRS and PHS suggests no advantage of using 
effects of PHS over PRS for age-specific risk prediction. Using less stringent significance 
thresholds for SNP selection, the age-specific risk prediction results are not significant by 
either PHS or PRS. To further enhance and validate the PHS approach for AD age at onset 
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risk prediction, a large Cox regression GWAS needs to be conducted, and used for SNP 
prioritization prior to construction of the PHS for each individual.  
We have demonstrated that PRS is a robust measure of the genetic liability to Alzheimer’s 
disease. In addition to general AD risk, it predicts the age specific risk of AD. The PHS, 
when constructed using significant SNPs identified by case/control GWAS, has potential 
disadvantages which are similar to PRS, as outlined in Tan et al (2018)18.  Development 
of PHS based up on Cox Hazard Regression model GWAS is a potential way forward to 
validate the PHS approach.   
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Table 1. APOE variants and the 31 SNPs and, their closest genes, log hazard ratio 
estimates used for PHS construction in Desikan et al (2017)10, and their odds ratio 
estimates as in Lambert et al., 20136. 
 
SNP Chr Position Gene Β=log(HR) 
Desikan et al  
(2017) 
−log10(p-
value)  
Desikan et 
al (2017) 
B=log(OR) 
in IGAP 
B=log(OR) 
IGAP_ 
noGERAD 
A1  
IGAP_ 
noGERAD 
APOE ε2 19  APOE −0.47 >15.0 -0.66 * -0.49** ε2 
APOE ε4 19  APOE 1.03 >20.0 1.12 * 0.66** ε4 
rs4266886 1 207685786 CR1 −0.09 2.7 -0.1542 0.1520 T 
rs61822977 1 207796065 CR1 −0.08 2.8 -0.0805 -0.0820 A 
rs6733839 2 127892810 BIN1 −0.15 10.5 -0.1880 0.1807 T 
rs10202748 2 234003117 INPP5D −0.06 2.1 -0.058 -0.0603 A 
rs115124923 6 32510482 HLA-DRB5 0.17 7.4 0.1216 -0.0973 A 
rs115675626 6 32669833 HLA-DQB1 −0.11 3.2 -0.1246 0.1040 A 
rs1109581 6 47678182 GPR115 −0.07 2.6 -0.0651 0.0601 T 
rs17265593 7 37619922 BC043356 −0.23 3.6 -0.0659 -0.0620 T 
rs2597283 7 37690507 BC043356 0.28 4.7 0.0679 0.0629 A 
rs1476679 7 100004446 ZCWPW1 0.11 4.9 0.1741 0.0712 T 
rs78571833 7 143122924 AL833583 0.14 3.8 0.0795 0.2083 A 
rs12679874 8 27230819 PTK2B −0.09 4.2 -0.0795 -0.0748 A 
rs2741342 8 27330096 CHRNA2 0.09 2.9 0.0916 -0.0872 T 
rs7831810 8 27430506 CLU 0.09 3.0 0.083 -0.0774 A 
rs1532277 8 27466181 CLU 0.21 8.3 0.1385 -0.1271 T 
rs9331888 8 27468862 CLU 0.16 5.1 0.0819 -0.0806 C 
rs7920721 10 11720308 CR595071 −0.07 2.9 -0.0713 -0.0660 A 
rs3740688 11 47380340 SPI1 0.07 2.8 0.0724 0.0739 T 
rs7116190 11 59964992 MS4A6A 0.08 3.9 0.0991 -0.0968 A 
rs526904 11 85811364 PICALM −0.20 2.3 -0.1188 -0.1130 T 
rs543293 11 85820077 PICALM 0.30 4.2 0.1257 -0.1192 A 
rs11218343 11 121435587 SORL1 0.18 2.8 0.2697 0.2539 T 
rs6572869 14 53353454 FERMT2 −0.11 3.0 -0.0947 0.1006 A 
rs12590273 14 92934120 SLC24A4 0.10 3.5 0.1348 0.1231 T 
rs7145100 14 107160690 abParts 0.08 2.0 0.1047 -0.1081 C 
rs74615166 15 64725490 TRIP4 −0.23 3.1 -0.3358 -0.2986 T 
rs2526378 17 56404349 BZRAP1 0.09 4.9 0.0762 0.0754 A 
rs117481827 19 1021627 C19orf6 −0.09 2.5 -0.1288 -0.1059 T 
rs7408475 19 1050130 ABCA7 0.18 4.3 0.0971 -0.0973 C 
rs3752246 19 1056492 ABCA7 −0.25 8.4 -0.1345 -0.1308 C 
rs7274581 20 55018260 CASS4 0.10 2.1 0.139 0.1497 A 
  
First 6th columns are the same as they were presented in Desikan et al (2017)10, followed 
by effect sizes from IGAP and IGAP_noGERAD summary statistics and reference allele 
as it was presented in IGAP. 
 
*- B estimated on GERAD data when running LR  
**- B estimated on GERAD data when running Cox regression  
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Table 2. Cox regression analysis results using PHS and PRS based upon (the same) 
SNPs as in Desikan et al (2017)10 in GERAD dataset.  
  
 APOE(ε2+ε4) 
 
25 SNPs APOE(ε2+ε4)+25 SNPs Compare: 
APOE 
vs 25 SNPs+ 
APOE(ε2+ε4)
p-value B 
[se] 
p-value B 
[se] 
p-value B* [se], 
 
B** [se] 
p-value 
PHS model with 
effect sizes from 
Desikan et al 
(2017) 
0.41 
[0.019] 
1.8x10-101 0.11 
[0.02] 
9.7x10-8 0.41 0.019], 
0.11 [0.02] 
4.8x10-103 
 
3.4x10-8 
PRS model with 
effects from 
IGAP_noGERAD 
0.408 
[0.018] 
2.7x10-103 0.13 
[0.02] 
1.9x10-10 0.41 [0.019], 
0.13 [0.02] 
2.4x10-105 
 
8.8x10-10 
 
*- B is a coefficient for APOE (ε2+ε4) 
**- B is a coefficient for PRS/PHS without APOE 
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Table 3. Cox regression analyses results of 5-fold cross-validation for PHS and PRS in 
GERAD dataset. 
 
Legend. First column shows the p-value thresholds for AD associated SNP selection (from 
an independent IGAP_noGERAD data). Second column represents the number of SNPs 
that were included to the PRS/PHS score. PHS and PRS effect sizes (mean and SD) and 
averaged p-values across 5-fold cross-validation subsampling are shown in columns 3-6. 
The last column shows the average of Pearson’s correlation coefficients between PHS and 
PRS. 
 
 
 
SNP  
selection 
p-value 
threshold 
N SNPs PHS PRS Correlation 
between 
PHS and 
PRS B 
[sd] 
p-value B 
[sd] 
p-value 
5x10-8 31 0.28 
[0.04] 
4.3x10-13 0.28 
[0.04] 
2.5x10-12 0.96 
10-5 80 0.26 
[0.02] 
2.8x10-11 0.29 
[0.05] 
5.7x10-11 0.79 
10-3 1460 0.13 
[0.025] 
3.4x10-3 0.18 
[0.04] 
1.9x10-4 0.17 
0.05 29998 0.07 
[0.027] 
0.12 0.1 
[0.034] 
0.04 0.21 
0.1 49247 0.06 
[0.031] 
0.18 0.09 
[0.028] 
0.05 0.27 
0.5 128952 0.08 
[0.024] 
0.07 0.08 
[0.035] 
0.13 0.42 
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Table 4. Cox regression analysis results of 5-fold cross-validation for PHS and PRS in 
GERAD dataset for individuals age at onset 55 and above. 
 
Legend. First column shows the p-value thresholds for AD associated SNP selection (from 
an independent IGAP_noGERAD data). Second column represents the number of SNPs 
that were included to the PRS/PHS score. PHS and PRS effect sizes (mean and SD) and 
averaged p-values across 5-fold cross-validation subsampling are shown in columns 3-6. 
The last column shows the average of Pearson’s correlation coefficients between PHS and 
PRS. 
 
 
 
P-value 
threshold 
N SNPs PHS PRS Pearson’s 
correlation 
between 
PHS and PRS B 
[sd] 
p-value B 
[sd] 
p-value 
5x10-8 31 0.3 
[0.01] 
1.3x10-12 0.29 
[0.03] 
5.8x10-12 0.96 
10-5 80 0.25 
[0.05] 
8.4x10-7 0.31 
[0.04] 
5.3x10-10 0.76 
10-3 1460 0.12 
[0.04] 
0.03 0.1 
[0.03] 
0.03 0.16 
0.05 29998 0.03 
[0.04] 
0.42 0.004 
[0.02] 
0.62 0.32 
0.1 49247 0.04 
[0.03] 
0.34 0.001 
[0.02] 
0.62 0.4 
0.5 128952 0.05 
[0.03] 
0.29 0.008 
[0.02] 
0.59 0.59 
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Figure 1. Histogram of age of AD cases and controls in the GERAD dataset. 
Figure 2. Scatter plot of individual’s PRS and PHS that were derived using 25 SNPs from 
Desikan et al (2017)10 in the GERAD sample. 
Figure 3. Survival curves for PHS and PRS scores + APOE ε4 and ε2 risk alleles for 
8,415 individuals (2,384 cases and 6,031 controls) for whom APOE genotypes were 
available. Individuals are split into 5 groups based on 0-5%, 5- 25%, 25-75%, 75- 95%, and 
95-100% of PHS/PRS distributions. 
Figure 4. Results of age-specific predictions using PRS and PHS analyses in GERAD 
subsamples of 20%, 40%, 60%, 80%, and 100% randomly selected individuals. The PHS 
and PRS are derived based upon 25 SNPs reported by Desikan et al (2017)10. 
 
Supplementary Table1. Sample size and descriptive statistics for the GERAD dataset. 
Legend. First column shows descriptive characteristics for the whole GERAD data 
(number of cases and controls and corresponding  % of females and mean age). Other 
columns show the same characteristics for each individual cohort that are part of GERAD 
dataset. 
 
Supplementary File1. GERAD authorship list. 
Legend. File contains all authors that contributed to GERAD consortium, their email 
addresses, affiliations and contribution. 
 
 
 
 




